22 related articles for article (PubMed ID: 23073516)
1. P53 and survivin expression in renal cell carcinoma.
Radovanović M; Petrović M; Šantrić V; Milojević B; Zubelić A; Isaković A
Urol Ann; 2023; 15(2):186-190. PubMed ID: 37304521
[TBL] [Abstract][Full Text] [Related]
2. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
3. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
4. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma.
Ljungberg B; Bozoky B; Kovacs G; Stattin P; Farrelly E; Nylander K; Landberg G
Scand J Urol Nephrol; 2001 Feb; 35(1):15-20. PubMed ID: 11291681
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 protein expression in renal cell carcinoma: comparison of two antibodies.
Walsh CJ; Kay EW; Lynch T; Walsh M; Milburn C; McLean PA; Murphy D; Donovan M; Leader MB
Br J Biomed Sci; 1996 Sep; 53(3):179-81. PubMed ID: 8914341
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 and P53 in renal cell carcinoma: association with tumor subtypes.
Noroozinia F; Fahmideh AN; Yekta Z; Rouhrazi H; Rasmi Y
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):79-84. PubMed ID: 24434386
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic prognostic indicators for renal cell carcinoma.
Delahunt B
Semin Diagn Pathol; 1998 Feb; 15(1):68-76. PubMed ID: 9503507
[TBL] [Abstract][Full Text] [Related]
9. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma.
Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Orsola I
Urology; 2005 Jan; 65(1):49-54. PubMed ID: 15667862
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects.
Kashyap MK; Kumar A; Emelianenko N; Kashyap A; Kaushik R; Huang R; Khullar M; Sharma SK; Singh SK; Bhargave AK; Upadhyaya SK
Biomarkers; 2005; 10(4):258-94. PubMed ID: 16191485
[TBL] [Abstract][Full Text] [Related]
11. Investigation of tumour supressor protein p53 in renal cell carcinoma patients.
Hodorova I; Solar P; Mihalik J; Vecanova J; Adamkov M; Rybarova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):44-9. PubMed ID: 23073516
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
